News archive

By screening red blood cell proteins in a protein database (ARVEXIS), Gavin Wright and his team from the Wellcome Trust Sanger Institute in Hinxton, UK, have identified a receptor-ligand pair which is of fundamental significance regarding the invasion of human red blood cells by Plasmodium falciparum, the malaria pathogen.

Between the 3rd and 4th of November 2011, more than twenty participants from university medical faculties, science and technology institutes, companies and government bodies took part in the first Cultex workshop in Hannover, Germany, devoted to current inhalation toxicity issues.

An experiment conducted by the Institute of Micro and Nanomaterials at the Ulm University demonstrates that it may be possible to develop a new treatment for Alzheimer’s disease using an active agent from green tea in combination with red laser light.

The number of experiments conducted on animals once again rose in 2010, according to a report published by the German Federal Ministry of Food, Agriculture and Consumer Protection (BMELV).

International Epigenome Project kicks off

Sunday, 30 October 2011 09:52

At the beginning of October, the first major European project of the "International Human Epigenome Project" (IHEC) started in Amsterdam. The project is an international joint cooperation and includes German scientists.

iPS from human Urine

Friday, 21 October 2011 10:02

Recently a research team from Austria and China succeded in producing induced pluripotent stem cells (iPS) from human urine. They have applied to patent the method.

A patent application from 1997 by the well-known stem cell researcher Prof. Dr. Oliver Brüstle has been rejected in the Luxembourg courts.

Researchers at the Max Delbrück Center of Molecular Medicine (MDC) in Berlin-Buch have for the first time developed a mathematical model with which genetic risk factors for the development of Alzheimer’s disease can be determined.

New pharmaceuticals have to be tested for cardiac toxicity before being introduced into market. Vice versa, a recall of a pharmaceutical product which has already been introduced into the market can often be traced to detrimental effects to the human heart.

From 1 January 2012, postgraduates and junior professors can receive financial support of up to 20 000 euro per year during the early phase of their scientific work. Young researchers in comparable positions will also be eligible, such as independent leaders of junior research groups.